AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT FOR MASITINIB IN THE TREATMENT…
News
Fandifi Partners with Dziki Warszawa
Vancouver, British Columbia–(Newsfile Corp. – June 1, 2023) – Fandifi Technology Corp. (CSE: FDM) (OTCQB:…
Synovus to participate in KBW US Regional Leaders Bank Conference
COLUMBUS, Ga.–(BUSINESS WIRE)–Synovus Financial Corp. (NYSE: SNV) will participate in the KBW U.S. Regional Leaders…
Doubleview Is Pleased to Announce Drill Hole Assay Results and Strong Mineralization Connects West Lisle Mineralization with the Main Lisle Mineralization
Vancouver, BC, Jun 1, 2023 – (ACN Newswire) – Doubleview Gold Corp. (TSXV: DBG) (OTCQB:…
Doubleview Is Pleased to Announce Drill Hole Assay Results and Strong Mineralization Connects West Lisle Mineralization with the Main Lisle Mineralization
Vancouver, British Columbia, June 1, 2023 – (ACN Newswire) – Doubleview Gold Corp. (TSXV: DBG)…
CORRECTING and REPLACING The Blair Agency Joins LTC Global
FORT MYERS, Fla.–(BUSINESS WIRE)–First sentence in the “About The Blair Agency” boilerplate should read: Headquartered…
Impossible Cloud Launches Partner Program to Help Resellers and Others Capitalize on Web3
Partner-Friendly Program Eases Collaboration and Integration of S3-Compatible Enterprise-Grade Cloud Solutions Built on Web3 Technology…
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Cutera, Inc. (CUTR) Investors
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
Publix Pharmacies Turn to OrderInsite Solutions to Prepare for Hurricane Season
NASHVILLE, Tenn. & LAKELAND, Fla.–(BUSINESS WIRE)–OrderInsite, an industry-leading technology platform for pharmacies to manage, monitor…
Hitachi Vantara Introduces Data Reliability Engineering Services to Optimize Data Ecosystems
The latest offering through Hitachi Application Reliability Centers empowers data-driven leaders with trustworthy, secure and…
Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company…
Excision BioTherapeutics Appoints Former Pfizer Chairman and CEO Jeffrey B. Kindler to its Board of Directors
SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company…
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a…
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
Seer’s Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a…
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”),…
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”),…
Aleafia Health Announces Extension of Forbearance Under Loan Agreement With Senior Lender
TORONTO, June 01, 2023 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQB: ALEAF) (“Aleafia…
Aleafia Health Announces Extension of Forbearance Under Loan Agreement With Senior Lender
TORONTO, June 01, 2023 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQB: ALEAF) (“Aleafia…
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus…
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
– YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus…